<<Hard to say. The amount would be whatever the Court decides, if this matter ever gets to Court (which I doubt will happen).>>
I agree but the bigger question is, why does MNTA tank at every opportunity? It truly puzzles me. It would be hard for anyone with a ounce of common sense to not to see through this and conclude rather quickly that it was a trivial development. Instead MNTA get hammered and was down 9% at one point today.
One would think a company who has a more than reasonable shot to provide a generic for a 3 billion dollar branded drug in the next few months (and quite likely the ONLY one in the space for an extended period ) would have more respect from the market than that. Even the 3x related sell off (which was clearly a negative development in terms of initial uptake %) seemed overdone if one were to consider the bigger picture.
I honestly do not get the lack of respect for MNTA. What am I missing???? Perhaps the mEnox experience is the cause, fearing a repeat?? Honestly, I see more differences than similarities with mEnox to mCopx, but perhaps I am just being naive.
Market Data 
Markets 
AI
